Skip to main content
PLOS Pathogens logoLink to PLOS Pathogens
. 2021 Mar 31;17(3):e1009476. doi: 10.1371/journal.ppat.1009476

Intestinal-epithelial LSD1 controls goblet cell maturation and effector responses required for gut immunity to bacterial and helminth infection

Naveen Parmar 1, Kyle Burrows 2,3, Pia M Vornewald 1, Håvard T Lindholm 1, Rosalie T Zwiggelaar 1, Alberto Díez-Sánchez 1, Mara Martín-Alonso 1, Madeleine Fosslie 4, Bruce A Vallance 5, John Arne Dahl 4, Colby Zaph 6, Menno J Oudhoff 1,*
Editor: Eric Oswald7
PMCID: PMC8041206  PMID: 33788902

Abstract

Infectious and inflammatory diseases in the intestine remain a serious threat for patients world-wide. Reprogramming of the intestinal epithelium towards a protective effector state is important to manage inflammation and immunity and can be therapeutically targeted. The role of epigenetic regulatory enzymes within these processes is not yet defined. Here, we use a mouse model that has an intestinal-epithelial specific deletion of the histone demethylase Lsd1 (cKO mice), which maintains the epithelium in a fixed reparative state. Challenge of cKO mice with bacteria-induced colitis or a helminth infection model both resulted in increased pathogenesis. Mechanistically, we discovered that LSD1 is important for goblet cell maturation and goblet-cell effector molecules such as RELMß. We propose that this may be in part mediated by directly controlling genes that facilitate cytoskeletal organization, which is important in goblet cell biology. This study therefore identifies intestinal-epithelial epigenetic regulation by LSD1 as a critical element in host protection from infection.

Author summary

The epithelium that lines our intestine has the important task of taking up nutrients, while also providing a barrier against pathogens. The intestinal epithelium performs these different tasks by having specialized cell types; enterocytes take up nutrients whereas goblet cells are in charge of producing a mucus layer. In addition, goblet cells can be stimulated to make special antimicrobial proteins. This occurs in response to cues called cytokines that come from immune cells, which are able to detect and act on the presence of pathogens such as bacteria or parasitic worms. In this study, we found that LSD1, an enzyme that controls gene expression, was important for goblet cells. Mice that lacked LSD1 specifically in their intestinal epithelium were unable to respond to cytokines and could not defend themselves against bacterial and parasitic infections. In part, we also made use of a specific inhibitor against the enzyme activity of LSD1. This inhibitor also blocked goblet cell differentiation and goblet-cell specific antimicrobial responses to cytokines. We are thus able to manipulate epithelial responses, which may be an important tool in the future to treat patients with infectious diseases.

Introduction

Gastrointestinal infections remain one of the most common causes for hospitalization worldwide [1]. These infections can be caused by diverse pathogens including bacteria, viruses, and parasites. Despite recent advances in treatment for infections, the increase in incidence of antibiotic resistant bacterial strains likely will ensure that infection remains a large threat to global health [2]. Therefore, increasing our understanding of disease mechanisms and exploring new options such as host-directed therapeutics remains a very important focus in basic research.

The intestinal epithelium is a crucial component of the gut barrier and is composed of a single layer of intestinal epithelial cells (IECs) including enterocytes, Paneth cells, goblet cells and tuft cells [3]. Several of these cell types are involved in the protection against pathogens. For example, Paneth cells that reside at the bottom of small intestinal crypts are a source of antimicrobial proteins such as lysozyme and α-defensins [4]. Likewise, goblet cells secrete mucins and antimicrobials that are effective against bacteria and protozoa [5]. On the other hand, tuft cells express IL-25 that is important in mounting a type 2 immune response to protect against certain helminths [6]. Finally, different pathogens elicit different immune responses that result in an alteration of the intestinal epithelial cell composition that is important for effector responses [7,8]. These epithelial effector responses are ultimately critical for immunity against intestinal pathogens.

In addition to epithelial effector mechanisms targeting pathogens, there is also a damage response upon inflammation or infection. There is a sequence of events that include migration and proliferation of epithelial cells, which eventually results in the re-establishment of mucosal homeostasis. To regain epithelial integrity after an insult, IECs are reprogrammed into a temporal reparative state that is required for repair [9,10]. Mice that lack the ability to reprogram towards such reparative state succumb from an otherwise manageable colitic insult [9,11]. However, it is unknown whether a reparative epithelial state prior to infection is beneficial for the host.

Chromatin accessibility has an important role in regulating gene expression. Chromatin accessibility can be mediated by posttranslational modifications of DNA and Histone proteins, which is done by epigenetic modifiers [12]. In the intestinal epithelium, the importance of maintaining epigenetic marks is exemplified by the finding that loss of the polycomb repressor complex 2 (PRC2) leads to a rapid loss of various cell types including intestinal stem cells, which subsequently leads to loss of tissue integrity and mice become moribund [1315]. We recently found an important role for the demethylase LSD1 in early-life intestinal epithelial development, including the differentiation of Paneth cells [16]. LSD1 can demethylate mono or di-methylated Histone 3 Lysine 4 (H3K4me1/2) that normally mark active or poised enhancers [17]. Importantly, we previously found that LSD1-deficient small intestinal epithelium is in a continuous state of repair[16].

Results

LSD1-deficient epithelium is in a reparative state during homeostasis

We have recently shown that inhibition or deletion of the histone demethylase LSD1 renders the small intestinal epithelium in a continuous state of repair, and this state is beneficial for recovery after irradiation injury[16]. We generated mice that lack Lsd1 in the intestinal epithelium specifically by crossing Villin-Cre mice with Lsd1f/f mice (conditional knock-out (cKO) mice) and found that these mice have a near complete deletion of Lsd1 in small intestinal epithelium (~10–20% of the epithelium still expressed LSD1 [16]). In the current study, we focus on the colon, and here we find 20–40% still expressing LSD1 in cKO mice (S1 Fig). So, the recombination in these mice is higher in the small intestine than in the large intestine. Nevertheless, we assessed whether the colonic epithelium in the cKO mice is in a general reparative state by examining different parameters such as proliferation and presence of the reparative marker Sca-1. Although we do not observe a significant increase in crypt length, we did find increased proliferation in colonic crypts of cKO mice compared to Lsd1f/f (WT) littermates as measured by Ki67+ cell counts (Fig 1A and 1B). In support, in small intestinal crypt derived organoids, we found that the Ki67+ proliferative zone was expanded and with increased intensity in cKO organoids compared to WT organoids (Fig 1C and 1D). Thus, increased proliferation is an intrinsic effect of Lsd1 deletion in intestinal epithelium. Two studies identified Sca-1 as a bona fide marker of repairing epithelium, and Sca-1-derived organoids partially retain this reparative state [9,18]. To test whether Lsd1-deficient epithelium contains Sca-1+ cells, we isolated colon crypts and analyzed Sca-1+ cells by flow cytometry. Indeed, we observed that crypt cells derived from cKO mice contain more Sca-1+ cells than their WT cage littermates (Figs 1E, 1F and S2A). Finally, IL-22 is known to be a crucial cytokine in the defense against pathogens, which among other responses is due to inducing epithelial repair [19], and by inducing antimicrobials such as REG3B and REG3γ [20]. To test if inhibition of LSD1 would affect the IL-22-induced antimicrobial responses, we co-treated WT organoids with GSK-LSD1, a potent LSD1 inhibitor that phenocopies Lsd1 deletion [16], and IL-22. We found that IL-22 induced STAT3 Tyr705 phosphorylation by western blot, and robustly induced Reg3b and Reg3g by qPCR independently of LSD1 enzymatic activity (Fig 1G, 1H and 1I). Together, these findings suggest that the intestinal epithelium of cKO mice is in a continuous reparative state and that this reparative state does not hamper IL-22-induced antimicrobial programs.

Fig 1. Intestinal epithelial Lsd1 deletion induces proliferation and a repair-like state in epithelium of mice.

Fig 1

(A) Immunofluorescent images of Ki67+ (green) in colonic epithelium of WT and cKO adult mice. DAPI was used as a nuclear counterstain. (B) Quantification of crypt length in naïve WT and cKO adult mice. Quantification of Ki67+ cells in colonic crypts of WT and cKO adult mice. n = 4 mice in each group, line is mean. (C) Organoids from WT and cKO mice were cultured for 3 days. The expression of Ki67+ (green) was determined by immunofluorescence. (D) Quantification of Ki67 intensity per organoid area in budding organoids from WT and cKO mice. Each dot represents 1 organoid. (E) Crypts cells were isolated from colon of WT and cKO adult mice and flow cytometric analysis of SCA1 was carried out. (F) Quantification of SCA1+ positive cells in crypts from WT and cKO adult mice, lines indicate littermate controls. n = 5 mice (G) Organoids were treated with GSK-LSD1 for 4 days followed by IL-22 stimulation for 30 minutes. Whole cell lysates were prepared and subjected to immunoblot analysis of p-STAT3, STAT3, and GAPDH. (H) Band intensity of pSTAT3 and STAT3 was measured using Image Studio Lite by LICOR. Each dot represents one biological replicate. (I) Organoids were co-cultured with GSK-LSD1 (5μM) and IL-22 (10 ng/ml) for 4 days in ENR (EGF, NOGGIN, R-SPONDIN) medium. The mRNA expression of Reg3b and Reg3g was determined by RT-qPCR relative to housekeeping gene Hprt. n = 3 biological replicates of a representative experiment. Unpaired two-tailed Student’s t test (B, D,H & I) was performed to observe significant differences. ns = not significant, * P ≤ 0.05, ** P < 0.01, *** P ≤ 0.001.

LSD1 is required for defense against Citrobacter rodentium

Citrobacter rodentium, a gram-negative mucosal bacterium, is used to model the pathogenesis of human enteric pathogens such as enteropathogenic Escherichia coli [21]. It is currently unknown whether having an epithelial reparative state prior to infection is beneficial for the host. Therefore, we orally infected cKO and WT littermates with C. rodentium. Strikingly, we found that cKO mice are susceptible to C. rodentium with increased mortality and increased weight loss compared to WT littermates (Fig 2A and 2B). We also found an increase in the number of C. rodentium bacteria in the stool of cKO mice compared to WT mice at day 6 (Fig 2C), but no increased C. rodentium numbers in liver and spleen (Fig 2D). An appropriate immune response is important in the defense against C. rodentium. We found near identical responses when assessing cytokine levels of IL-22, IL-17A, and IFN-γ in the colon by qPCR or in re-stimulated mesenteric lymph node cells by ELISA (Fig 2E and 2F). The intestinal barrier plays an important role in blocking the entry of pathogenic microorganisms from the lumen into the circulation. The increased susceptibility of cKO mice towards C. rodentium prompted us to measure intestinal permeability in animals by orally administering FITC dextran. We observed that infection clearly led to increased permeability as measured by FITC dextran levels in the serum (Fig 2G). However, we did not observe any significant differences between infected cKO and WT mice (Fig 2G). Thus, although cKO were highly susceptible to infection, their immune response and their initial barrier function was not atypical.

Fig 2. LSD1-deficient epithelium renders mice susceptible to C. rodentium.

Fig 2

(A) Survival plot of WT and cKO mice after C. rodentium infection. Kaplan-Meier survival curves was used and tested with a Gehan-Breslow-Wilcoxon test to identify significant differences between wild-type and cKO mice (p value = 0.0405). (B) Body weight loss comparing Naive, WT and cKO mice during C. rodentium infection. n = 9 (naive), n = 16 (WT) and n = 14 (cKO) mice, three pooled experiments. Data points are mean and SD. (C) Stool CFU (colony forming units) counts in WT (n = 22) and cKO (n = 21) infected mice using plating on agar after 6 days of C. rodentium infection. (D) CFU counts in liver and spleen tissue of WT (n = 12) and cKO (n = 11) mice at day 6 post C. rodentium infection. (E) RT-qPCR for Il22, Il17a and Ifng was carried out in colon tissue from naive (n = 10), WT (n = 12) and cKO (n = 11) mice infected with C. rodentium for 6 days. Expression is relative to Hprt. (F) ELISA for IL-22, IL-17A and IFN-γ in re-stimulated mesenteric lymph node cells after 6 days of C. rodentium infection. (G) Measurement of FITC dextran fluoroscence in serum derived from (naive = 4), WT (n = 4) and cKO (n = 4) infected with C. rodentium for 6 days. * P ≤ 0.05, ** P ≤ 0.01, Each dot represents one mouse, and means are depicted.

LSD1 regulates crypt length and goblet cell responses after C. rodentium infection

Next, we examined the epithelial response upon C. rodentium infection more closely. We found no differences in epithelial-derived antimicrobials, as measured by Reg3b and Reg3g mRNA levels in the colon comparing cKO with WT mice at day 6 post infection (Fig 3A). This indicates that an appropriate immune response and an adequate induction of epithelial-derived antimicrobials in cKO mice is insufficient to prevent morbidity and mortality. It is known that crypt length and induction of goblet cells is essential for resistance against C. rodentium and that these are indicators of disease [22,23]. Histological studies revealed that there is an increase in colonic crypt hyperplasia in cKO mice compared to WT mice at day 6 post infection (Fig 3B and 3C), and that these long crypts are characterized by Ki67+ cells (Fig 3D). Next, we sought to determine the goblet-cell responses that are induced by C. rodentium infection. We found that C. rodentium infection led to induction of the goblet-cell effector gene Retnlb in WT mice, however, in stark contrast, this induction was completely absent in cKO mice (Fig 3E). This was supported by RELMß staining of colon sections, where, in infected WT mice high levels were detected, but this was virtually absent in tissues from infected cKO mice (Fig 3F and 3G). In addition, we found LSD1+ escaper crypts to be filled with RELMß+ goblet cells in cKO mice (S3A Fig). This further supports that there is an appropriate immune response in cKO mice, but cKO epithelium fails to respond properly. In summary, although IL-22-induced antimicrobials such as REG3γ are normally regulated, the proliferative and the goblet-cell responses are strongly dependent on epithelial LSD1 expression.

Fig 3. Intestinal-epithelial LSD1 is required for appropriate crypt hyperplasia and goblet cell responses to infection with C. rodentium.

Fig 3

(A) RT-qPCR for antimicrobials Reg3b and Reg3g in colon tissue of Naive (WT n = 10), and WT (n = 12) and cKO (n = 11) mice infected with C. rodentium for 6 days. (B&C) H&E staining and quantification of crypt length at distal colon in WT (n = 6) and cKO (n = 5) mice infected with C. rodentium for 6 days (scale bar = 50 μm). (D) Ki67 staining to measure proliferation in distal colon tissue of WT and cKO mice infected with C. rodentium for 6 days. (E) RT-qPCR for goblet-cell specific antimicrobials Retnlb in colon tissue of Naive (WT n = 10), WT (n = 12) and cKO (n = 11) mice infected with C. rodentium for 6 days. (F&G) Representative confocal images and quantification of RELMβ+ cells (green) in distal colon tissue of WT (n = 6) and cKO (n = 5) infected mice. DAPI (blue) was used as a nuclear counter stain. Scale bar = 50 μm. Unpaired two-tailed Student’s t test (A, C, E & G) was performed to observe significant differences among experimental groups. ns = not significant, * P ≤ 0.05, **, P < 0.01, *** P ≤ 0.001. Each dot represents one mouse and means are depicted.

LSD1 is required for optimal immunity against the helminth Trichuris muris

Resistance to intestinal infection is often an interplay between various cell types in which the epithelium is part of the effector mechanism. Trichuris muris is a murine whipworm that is closely related to the human parasite T. trichiura. Clearance of T. muris is dependent on a type 2 response that leads to increased epithelial turnover, in which the epithelium acts like an escalator to get rid of worms [24,25]. In addition, a type 2 response leads to goblet cell hyperplasia, which is also important [26]. To study the role of intestinal-epithelial LSD1 in response to T. muris, mice were infected with ~200 infective embryonated eggs by oral gavage and we included Rag1-/- mice as a positive control for the infection. We observed that parasite elimination was incomplete in cKO mice on day 21 post infection with similar worm counts as susceptible Rag1-/- mice, at which point nearly all WT littermates had cleared the infection (Fig 4A). Goblet cell hyperplasia is a hallmark feature and important for the elimination of worms from the ceacum [26,27]. Therefore, we carried out a histological examination of cKO and WT ceacums at day 21 post T. muris infection. Our Periodic acid-Schiff (PAS) staining revealed a near complete absence in goblet cells in the ceacum of T. muris infected cKO mice compared to infected WT mice (Fig 4B and 4C). In support, we found reduced expression of goblet-cell effector genes Retnlb and Clca1 in infected cKO mice compared to WT mice (Fig 4D) as well as a stark reduction in RELMß+ cells per crypt (Fig 4E and 4F). Similar to the response to C. rodentium, we found increased crypt length in cKO mice compared to WT mice (Fig 4G). Elimination of T. muris parasites is dependent on expression of type 2 cytokines. Analysis of the hallmark Th2 cytokine revealed that protein expression of IL-13 was almost similar in WT and cKO mice infected with T. muris (Fig 4H). However, the expression of the Th1 cytokine IFN-γ was upregulated in restimulated lymph node cells of cKO mice in comparison with WT littermates (Fig 4H). Therefore, we conclude that upregulated IFN-γ expression in infected cKO mice in combination with a lack of goblet cell responses renders these mice susceptible to T. muris infection.

Fig 4. Intestinal-epithelial LSD1 is required for effective immunity against the whipworm Trichuris muris.

Fig 4

(A) WT (n = 9), cKO (n = 9) and Rag1KO (n = 3) mice were infected with 200 embryonated eggs of T. muris. Worm burden was quantified in caecum after 21 days of infection. Pooled from 2 independent experiments. (B) PAS staining for goblet cells was done in ceacal epithelium of WT and cKO mice after 21 days of T. muris infection. (C) Quantification of PAS+ cells in caecal epithelium of WT (n = 8) and cKO (n = 9) mice after 21 days of T. muris infection. (D) RT-qPCR for Retnlb and Clca1 in proximal colon of WT (n = 8) and cKO (n = 8) after 21 days of T. muris infection. (E&F) Representative confocal images and quantification of RELMβ+ cells (green) in caecum tissue of WT (n = 8) and cKO (n = 9) mice infected with T. muris for 21 days. DAPI (blue) was used as a nuclear counter stain. Scale bar = 50 μm. (G) Measurement of cecal crypts length in WT (n = 8) and cKO (n = 9) mice infected with T. muris for 21 days. (H) Sandwich ELISA for quantification of IL-13 and IFN-γ expression in restimulated mesenteric lymph node cells after 21 days of T. muris infection. Unpaired two-tailed Student’s t test (A, C, D, F&G) and one-way ANOVA (H) was performed to observe significant differences. ns = not significant, * P ≤ 0.05, **, P < 0.01, *** P ≤ 0.001.

LSD1 controls homeostatic and cytokine driven goblet cell responses

In both C. rodentium and T. muris infection models we found a complete inability to induce goblet-cell effector molecules that are common in response to these infections. We have previously found a modest reduction in goblet cell numbers in small intestinal tissues of cKO mice [16]. However, we found that goblet cell maturation is much more impaired in the colons of naïve cKO mice, as shown by reduced numbers and by a lack of large MUC2+ and Ulex Europaeus Agglutinin-1 (UEA1)+ granules (Fig 5A and 5B). Similarly, we also found significant reduction of MUC2 protein levels and Muc2 gene expression in colon organoids derived from cKO mice compared to those from WT mice (Figs 5C, 5D, S5A and S5B). In support, we find that GSK-LSD1 also drastically inhibits goblet cell maturation in small intestinal derived organoids (S4A and S4B Fig).

Fig 5. LSD1 controls (immune-driven) goblet cell responses.

Fig 5

(A) Colon sections of WT and cKO mice were stained for MUC2 (green), Ulex europaeus agglutinin I (UEA1) (red). UEA1 is a lectin which binds to glycoproteins and glycolipids and used as an additional marker for goblet cells. DAPI (blue) used as a counterstaining. (B) Quantification of MUC2+ cells and UEA1+ cells in the colon of WT (n = 7) and cKO (n = 8) mice. (C) WT and cKO colon organoids were seeded in ENR for 4 days and immunofluorescent staining of MUC2 (green) and β- catenin (purple) was performed. (D) Quantification of MUC2 intensity per colon organoid is represented. Colon organoids were derived from WT (n = 2) and cKO (n = 2) mice. (E&G) Immunofluorescent confocal images for MUC2 (E, green) and RELMβ (G, green) in WT and cKO organoids left untreated in ENR or supplemented with IL-13 (10 ng/ml), IL-22 (5ng/ml) or DAPT 10 μM for 4 days. DAPI was used to stain nuclei (blue). (F&H), Quantification of MUC2 fluorescence intensity (F) and number of RELMβ positive cells (H) per organoid. (I) Representative bright field images of WT and cKO organoids treated with IL-13 (10 ng/ml), IL-22 (5ng/ml) and DAPT 10 μM for 4 days. Scale bar is 100μm. (J) Quantification of organoid area from minimal projections 4 days after seeding. Dots represents the mean of one well. Images are representative of 3 independent experiments. (K) cKO organoids were treated with IL-13 (10 ng/ml), IL-22 (5ng/ml) and combination of IL-13 + IL-22 for 4 days. Immunofluorescent images of RELMβ (green) and β-catenin (purple). (L) Quantification of RELMβ+ cells per organoid are shown. Unpaired two-tailed Student’s t test (B & D) and One-way analysis of variance with Tukey’s Multiple Comparison Test (F, H, J& L) was performed to observe significant differences. ns = not significant, * P ≤ 0.05, **, P < 0.01, *** P ≤ 0.001.

To test if we could rescue the lack of goblet cell maturation in LSD1-deficient intestinal epithelium, we treated organoids with the γ-secretase inhibitor DAPT, a well-established NOTCH inhibitor that leads to induction of goblet cells [28]. In addition, to define cytokine-induced goblet cell responses, we treated WT and cKO organoids with IL-13 or IL-22. As a readout, we used immunofluorescent staining of MUC2, a canonical goblet cell marker, and RELMβ, a goblet cell effector protein, both of which were normalized to organoid area. Expectedly, DAPT treatment induced goblet cell differentiation in WT organoids while limiting organoid growth (Fig 5E–5J). In contrast, although DAPT treatment led to reduced growth in cKO organoids, it did not significantly induce MUC2 levels per organoid area (Fig 5E and 5F). Similar to recent findings, IL-13 but not IL-22 robustly induced MUC2 in WT organoids [8], and this response was similar in cKO organoids (Fig 5E and 5F), suggesting that, in contrast to DAPT treatment, IL-13 can overrule the lack of goblet cell differentiation caused by LSD1 deficiency. DAPT did not induce RELMβ in either WT or cKO cultures (Fig 5G and 5H), which suggests NOTCH inhibition is not sufficient for RELMβ effector responses. In contrast, both IL-22 and IL-13 caused a dramatic increase in RELMβ+ cells in WT organoids, whereas there was only a subtle response in cKO organoid cultures (Fig 5G and 5H). Together, only IL-13 is able to stimulate MUC2+ goblet cell numbers in cKO organoids, but this is insufficient to induce the effector RELMβ. As IL-22 is a stronger inducer of RELMβ in WT organoids, we reasoned that perhaps incubation of IL-13, to allow for goblet cell differentiation, and IL-22 would induce RELMβ. Indeed, cKO organoids treated with both IL-13 and IL-22 led to a distinct induction of RELMβ+ cells (Fig 5K and 5L).

LSD1 inhibition results in rapid reduction of goblet cell maturation

Next, we resorted to a previously performed RNA seq experiment comparing small intestinal crypt cells from cKO mice with WT littermates, as well as RNA seq from 24h GSK-LSD1 treated organoids compared to untreated organoids [16]. Although these datasets were not generated from colon epithelium, we anticipated that LSD1-controlled mechanisms would be sufficiently comparable between colon and small-intestinal epithelium to provide mechanistic insight. Predictably, using gene set enrichment analysis, we found a negative correlation with a goblet cell gene set [29], both in the data from in vivo crypts and in vitro organoid experiment (Fig 6A). This suggests that within 24h, thus almost immediately after LSD1 inhibition, there is a block in goblet cell maturation.

Fig 6. LSD1 epigenetically controls modulators of the cytoskeleton.

Fig 6

(A) Application of GSEA of a goblet cell gene set in WT and cKO small intestine RNA seq, and untreated vs GSK-LSD1 (24h) treated organoids RNA-seq data. (B) Top 500 genes upregulated in cKO crypts were selected and unbiased association with the top 20 GO terms is displayed. (C) Genes taken from in 6B bold-selected GO terms are displayed in a heatmap using Transcripts Per Million (TPM) values scaled to the max of the gene comparing WT and cKO crypts (left) and untreated and GSK-LSD1 (24h) treated organoids (right). (D) Mean ATAC signal of normalized peak density surrounding previously identified H3K4me1 peaks that are significantly up in cKO crypts compared to WT crypts. Representative graph from n = 2. (E) Representative Integrative Genomics Viewer (IGV) tracks of H3K4me1 and ATAC signal at the Flna locus (n = 2). (F) IGV tracks of H3K4me1 and LSD1 levels at the FLNA locus in a human cancer cell line. (G) Representative confocal images of FILAMIN A (FLNA) stained in WT and cKO organoids. Quantification of FLNA intensity in WT and cKO organoids. (H) WT organoids were untreated (ENR) or treated (GSK-LSD1- 5 μM) for 4 days and then stained for FLNA (green). DAPI was used as a counter stain (blue). Scale bar = 50 μm Organoids were quantified for FLNA fluorescent intensity. (I) FLNA staining in paraffin embedded colon sections of naive WT and cKO mice. White Arrow indicates the increased FLNA expression on the apical side of colonic crypts. Scale bar = 50 μm. Unpaired Student’s t test was performed to observe significant differences. *** P ≤ 0.001.

LSD1 inhibits genes associated with cytoskeletal organization by controlling chromatin accessibility

To identify other prominent gene programs or processes regulated by LSD1, we performed an unbiased analysis of gene ontology (GO) terms associated with the top 500 upregulated genes in cKO crypt cells compared to WT crypt cells (Fig 6B). We found several terms associated with the regulation of actin and cytoskeletal processes to be enriched in cKO crypts (Fig 6B). Importantly, unlike the goblet cell gene set signature, the genes associated with ‘cytoskeletal organization’ GO terms that are higher expressed in cKO crypts were not affected upon 24h GSK-LSD1 treatment in organoids (Fig 6C). We previously found that genes upregulated in cKO crypt cells associated with increased H3K4me1 levels at putative enhancer sites [16]. To test if increased H3K4me1 levels also led to functional changes in chromatin accessibility, we performed Assay for Transposase-Accessible Chromatin using sequencing (ATAC-seq) comparing WT and cKO small intestinal crypts. We found that genomic sites with significant H3K4me1 peaks that were identified previously also had increased ATAC levels, suggesting increased accessibility (Fig 6D). This also included genes associated with cytoskeletal organization, for example Flna, the gene for FILAMIN A (Fig 6E). In support, using a published LSD1 ChIP seq data set from a human cancer cell line [30], we found that LSD1 is located at the FLNA locus where there is also H3K4me1 (Fig 6F). Thus, this suggests that LSD1, by demethylating H3K4me1 levels at putative enhancer sites, directly controls these important mediators of the actin cytoskeleton. Knockdown of Flna in intestinal tumor organoids led to reduced stem cell marker expression and proliferation, suggesting it could affect proliferation and differentiation [31], and thus we explored its expression in organoids and colon of WT and cKO mice. We found increased protein level of FILAMIN A (FLNA) in cKO organoids and in organoids that were treated long-term with GSK-LSD1 (Fig 6G and 6H). Finally, increased FLNA protein levels were found in vivo in cKO colon epithelium where it accumulated at the apical side whereas it was virtually absent in WT colon epithelium (Figs 6I and S3B). Together, we suggest a model where changes in expression of cytoskeletal modulators such as FLNA depends on remodelling of chromatin accessibility.

LSD1-controlled cytoskeletal organization partially control goblet cell responses

We found that LSD1 is required for goblet cell maturation and effector responses, and that direct NOTCH inhibition by DAPT treatment was insufficient to overcome this deficiency in cKO epithelium (Fig 5E). However, IL-13, which also induces goblet cells by inhibiting NOTCH signalling, was able to induce MUC2 expression (Fig 5E). In addition, IL-13 also affected cKO but not WT organoid growth (Fig 5I and 5J). Importantly, IL-13 does not only inhibit NOTCH, it is also known to induce cytoskeletal changes, which is perhaps best described in macrophage differentiation [32]. As the expression of cytoskeletal modulators is controlled by LSD1, we reasoned that IL-13 thus can overcome this deficiency by affecting both cytoskeletal features and NOTCH signalling. Furthermore, the cytoskeletal network itself plays an important role in intestinal epithelial cell differentiation [33]. In this study, Petersen et al. used the ROCK inhibitor Y-27632 in mice and organoids and found that this altered cytoskeletal properties and resulted in increased secretory cell differentiation including goblet cells. To test if ROCK inhibition would induce goblet cell maturation in cKO epithelium, we treated cKO-derived organoids with Y-27632. We found that Y-27632 treatment resulted in reduced growth, but modestly increased MUC2 levels per organoid (Fig 7A–7D). To test if altering ROCK inhibition would also allow for IL-22 mediated goblet cell effector responses, we treated cKO organoids with a combination of IL-22 and Y-27632. We found that Y-27632 limited IL-22 induced growth, and also limited organoid budding (Fig 7E and 7F). Furthermore, Y-27632 enhanced RELMβ expression in IL-22 treated cKO organoids compared to IL-22 treatment alone (Fig 7G and 7H). Similarly, using sustained GSK-LSD1 treated organoids, we found that Y-27632 also induced RELMβ expression in IL-22 treated organoids (Fig 7I and 7J). Together, this work suggests that LSD1 may affect goblet cell differentiation and effector responses in part by controlling the cytoskeletal organization.

Fig 7. Cytoskeleton manipulation partially rescues goblet cell maturation in LSD1-deficient organoids.

Fig 7

(A) cKO organoids were left untreated (ENR) or treated with Y-27632 (10 μM) for 4 days. Representative bright field images are shown. Scale bar is 100 μm. (B) Quantification of organoid area from minimal projections 4 days after seeding. Dots represents mean of one well, pooled from 3 independent experiments. (C&D) Representative immunofluorescent images of MUC2 (green) and β-catenin (purple). MUC2 fluorescence intensity relative to organoid area was measured. Scale bar is 50 μm. (E) cKO organoids were treated with IL-22 (5ng/ml) or IL22+ Y-27632) for 4 days. Representative bright field images are shown. Scale bar is 100 μm. (F) Mean organoid area of cKO organoids is depicted as well as the percentage of spheroids in each well 4 days after seeding. (G) cKO organoids were left untreated (ENR) or treated with IL-22 (5ng/ml), Y-27632 (10 μM) and combination of Y-27632 and IL-22 for 4 days and representative images for RELMβ (green) and β-catenin (purple)staining are shown. (H) Pooled quantification of RELMβ+ cells per organoid area from independent experiments. (I) WT organoids were pre-treated with GSK-LSD1 for 7 days. Next, these organoids were treated with combination of IL-22 (5ng/ml) + GSK-LSD1 and GSK-LSD1+ IL-22+ Y-27632 for 4 days. Immunofluorescence images of RELMβ (green) and β-catenin (purple) are shown. (J) Quantification of RELMβ+ cells per organoid area is shown. Unpaired two-tailed Student’s t test (B, D, F, H & J) was performed to define significance. * P ≤ 0.05, **, P < 0.01, *** P ≤ 0.001.

Discussion

The gastrointestinal system is continuously exposed to various pathogens, chemicals, and dietary components that can result in inflammation and tissue damage. It was previously found that the epithelium, after damage or infection, temporarily transitions into a reparative fetal-like state that is necessary to regain homeostasis [9,18]. Thus, drugs that would induce this transition of the epithelium could be attractive therapeutics used in patients with infection or inflammatory bowel disease to aid in the tissue repair, or even prevent disease. Indeed, in a previous report, we showed that reparative epithelium is beneficial upon irradiation injury and that LSD1 is a druggable target that could facilitate the reprogramming [16]. In addition, treating mice with GSK-LSD1 upon damage alleviates colitis symptoms in DSS-colitis [34]. In this study, we tested whether a pre-existing epithelial reparative state, such as in LSD1 cKO mice, would be beneficial in infectious disease models. We found that LSD1 cKO mice are susceptible to two different infectious disease models. Mechanistically, we find clear evidence that goblet cell effector genes rely on LSD1, both under homeostasis and upon induction in the diverse disease models. In addition, using an unbiased analysis of previous RNA-seq data, we found that genes associated with modulation of the cytoskeleton are regulated by LSD1. As an example, we find that the gene encoding for FILAMIN A, a protein involved in mechanosensing and mechanotransduction [35], is likely a direct target of LSD1 demethylase activity. This could also explain how LSD1 mediates genes that are controlled by the mechanosensing regulatory proteins YAP/TAZ, including the reparative gene set, such as we found previously [16]. Further studies are needed to elucidate the exact role of FILAMIN A and other cytoskeletal modulators in LSD1-controlled intestinal epithelial biology.

LSD1 was the first histone demethylase discovered and has been primarily studied in developmental biology and cancer. Of note, it is currently a target in several clinical trials for the treatment of cancers. Our data suggests that these patients may experience higher susceptibility to gastrointestinal insults. Nevertheless, the mode of action of LSD1 in the various systems is not always clear. For example, it was found that inhibition of LSD1 leads to differentiation of myeloid leukemia cells, but that this was due to the scaffolding function of LSD1, rather than its histone demethylase activity [36]. This last part fits with our finding of the immediate loss of goblet cell differentiation upon inhibition of LSD1, which could be independent of H3K4me1/2 enhancer modulation by LSD1, which we would expect to lead to more transient changes in cell lineage choice. Indeed, LSD1 inhibition can lead to the disassociation of the LSD1-GFI1 co-repressor complex as was previously suggested and reported [16,36]. In support, GFI1 KO mice have reduced goblet cell differentiation maturation [37]. The classical mode of action by LSD1 however is demethylation of enhancer regions [38]. The kinetics that would affect these genes may be a bit slower, and this is indeed what we observe in the regulation of cytoskeletal-modulation associated genes such as Flna. We propose that this latter mechanism is also important in the control of goblet cell differentiation and effector responses, such as those induced by IL-13 and IL-22.

Material and methods

Ethics statement

Mice were maintained at the Comparative Medicine Core Facility (CoMed) at NTNU and at the Biomedical Research Centre at the University of British Columbia. C. rodentium experiments were ethically approved by the Norwegian Food Safety Authority (FOTS ID 11842). T. muris experiments were approved by the University of British Columbia Animal Care Committee (protocol number A13-0010) in accordance with the Canadian Guidelines for Animal Research.

Mouse strains

Villin-Cre were a kind gift from Sylvie Robine [39], Lsd1f/f mice were a kind gift from Dr. Stuart Orkin [40], and Rag1-/- mice were obtained from Jackson laboratories. Mice breeding was carried out and were housed at the Comparative Medicine Core Facility (CoMed).

Citrobacter rodentium infection and CFU counts

Citrobacter rodentium infection studies were performed following the guidelines and recommendations for the care and use of animals in research and were approved by Norwegian Food Safety Authority (FOTS ID: 11842). Briefly, GFP-expressing C. rodentium [22] was grown at 37°C in Luria- Bertani (LB) medium supplemented with chloramphenicol (30 μg/ml). 6–10 weeks old male and female littermates were infected by oral gavage with overnight culture of 108–109 CFU per mouse delivered in a volume of 0.1ml sterile PBS. Mice were daily monitored after the oral administration with C. rodentium and assessed for weight loss and other pain associated behaviors like hunchbacked posture, rectal prolapse and piloerection. Fecal samples were collected, weighed and homogenized in a sterile PBS using FastPrep homogenizer from MP biomedicals. Serially diluted homogenates were plated on chloramphenicol resistant agar plates and number of colonies were counted after incubation of plates at 37°C for 18–24 h. At the end of every experiment, mice were humanely euthanized by inhalation of CO2.

Trichuris muris infection in mice

Trichuris infections were performed at the University of British Columbia following institutional guidelines. Briefly, both male and female littermates were infected by oral gavage with high dose of approximated 200 embryonated T. muris eggs. After 21 days of T. muris infections, mice were sacrificed for the analysis of worm burden and other gut associated parameters in the ceacum.

Immunofluorescence and immunohistochemistry staining of tissue sections

After sacrificing the mice, segments of intestinal mouse were dissected and washed with sterile PBS and then rolled in a swiss roll. Intestinal tissue was fixed with 4% formaldehyde for 48 h at room temperature. Tissue was subsequently dehydrated through a series of ethanol graded and then embedded in the paraffin wax blocks. 5 μm thick sections were prepared using a microtome and tissue was placed on glass slides. The tissue slides were then deparaffinized and rehydrated, followed by antigen retrieval (Citrate buffer pH-6.0 for all staining and Tris EDTA buffer pH-9.0 for Filamin A). Sections were blocked in blocking buffer (1% BSA and 2% normal goat serum) for 1 h at room temperature in a humidified chamber. Tissue were incubated with diluted primary antibody (LSD1, 1:200 Cell Signaling Technology 2184, MUC2 1:200 Santa Cruz Biotechnology sc-15334, anti Ki67 1:200 Invitrogen MA5-14520, RELMβ 1:1000, Peprotech 500-p215, Filamin A 1:200 Invitrogen PA5-82043 overnight at 4°C. Next day, slides were washed with 0.2% PBST for 10 min. Tissue was incubated with secondary antibody coupled to fluorochromes, UEA-1 (1:500 Vector Laboratories RL-1062) and counterstained with DAPI for 1 h at room temperature in the dark. After incubation, slides were washed 3 times with 0.2% PBST for 10 mins each and then mounted in Fluoromount G. Hematoxylin and Eosin (H&E) staining and Periodic Acid Schiff (PAS) staining in paraffin sections was performed according to the standard histological procedures.

RNA isolation and qPCR

Total RNA was isolated from organoids and colon tissue using the Quick-RNA MicroPrep Kit (Zymo Research). Briefly, organoids were first lysed in RNA-Solv Reagent provided by Omega Biotek. For RNA isolation from colon tissue, small piece of colon tissue was first homogenized using FastPrep homogenizer and was resuspended in RNA-Solv Reagent. After lysis, cell lysates were centrifuged at ≥12,000 x g for 1 minute for the removal of particulate and supernatant was transferred to a fresh tube. Equal volume of ethanol (95–100%) was added to the sample and mixture was centrifuged in Zymo-Spin IC Column. DNase treatment was performed by adding DNase mix directly on to the column and incubated for 15 minutes. To wash the column, 400 μl RNA Prep Buffer to the column and centrifuge for 30 seconds and followed by 700 μl RNA Wash Buffer to the column and centrifuge for 30 seconds. To ensure complete removal of wash buffer, 400 μl RNA of Wash Buffer was added and column was centrifuged for 2 minutes at 12,000 x g. RNA was eluted into the fresh tube in a volume of 20 μL for organoids and 40 μL for colon tissue by addition of DNase/RNase-Free water onto the column. The eluted RNA was used immediately or stored at -80°C for downstream use. Equal amount of purified RNA was reversed transcribed to cDNA using the Applied Biosystem High-Capacity RNA-to-cDNA Kit. Quantitative real-time PCR was performed using the StepOnePlus Real-Time PCR System by using both TaqMan Universal PCR Master Mix and SYBR Green PCR Master Mix by Applied Biosystem. All the primers used are represented in the supplementary table (S1 Table).

RNA Seq analysis

RNA sequencing data from intestinal epithelium with conditional LSD1 KO (accession E-MTAB-7862) and small intestinal organoids treated with GSK-LSD1 (accession E-MTAB-9077) were analyzed as described previously [16]. GSEA analysis was run with log2fold change as weights, 10000 permutations and otherwise default settings using the R-package clusterProfiler [41]. The clusterProfiler package was also used for GO-term analysis for terms in biological process. Heatmaps were created using the R-package pheatmap.

ChIP Seq analysis

H3K4me1 ChIP sequencing data from intestinal epithelium with conditional LSD1 KO was analyzed as described previously [16] (accession E-MTAB-7871) and processed bigwig files from LSD1 ChIP sequencing where downloaded from accession GSE66298 [30]. Plots of ChIP seq signal where made using integrative genomics viewer from bigwig files [42].

ATAC-seq

Sorted (Epcam+) small intestinal crypt cells were harvested and frozen in culture media containing FBS and 10% DMSO. Cryopreserved cells were sent to Active Motif to perform the ATAC-seq assay. The cells were then thawed in a 37°C water bath, pelleted, washed with cold PBS, and tagmented as previously described [43], with some modifications based on [44]. Briefly, cell pellets were resuspended in lysis buffer, pelleted, and tagmented using the enzyme and buffer provided in the Nextera Library Prep Kit (Illumina). Tagmented DNA was then purified using the MinElute PCR purification kit (Qiagen), amplified with 10 cycles of PCR, and purified using Agencourt AMPure SPRI beads (Beckman Coulter). Resulting material was quantified using the KAPA Library Quantification Kit for Illumina platforms (KAPA Biosystems), and sequenced with PE42 sequencing on the NextSeq 500 sequencer (Illumina).

ATAC-seq data was analysed with the same pipeline as analysis of ChIP-Seq data described in [16].

Mouse duodenum crypt isolation and organoids culture

We followed standard protocol for crypts isolation as described [45]. Briefly, we isolated 10 cm duodenum section of the WT and cKO mice. The duodenum was washed with ice-cold PBS and open longitudinally. Next, villi were scraped off using a glass coverslip and washed with ice-cold PBS. The duodenum tissue was cut into 2–4 mm small pieces and transferred to 50 mL falcon tube. These fragments were washed with ice cold PBS by up and down with a 10mL pipette coated with FBS. This step was repeated 10 times until supernatant turned fully clear. Next, these fragments were incubated with 30 mL ice-cold crypt isolation buffer (2mM EDTA in PBS) with gentle rotation in the cold room. After 30 minutes, fragments were settled down and supernatant was discarded. After this, fragments were pipette up and down with 20ml of PBS to release the villus and crypts. This step was repeated until most of crypts were released and passed through the 70-μm cell strainer and collected into FBS coated sterile 50ml falcon tube. The filtered fractions contain crypts and were spun down at 300 × g for 5 min and pellet was resuspended in 10 mL of ice-cold basal culture media. This fraction was washed with ice-cold basal culture media to remove the single cell at 200 × g for 2 mins. Next 10 μL of crypts from 10 mL resuspended fractions was taken and counted under light microscope. After this counting, crypts were centrifuged and resuspended in thawed Matrigel and 40 μL of the resuspended Matrigel droplet was added to well in pre-warmed 24 well plate. Organoids were grown and maintained in ‘basal crypt medium’ (Advanced DMEM/F12 supplemented with penicillin/streptomycin, 10 mM HEPES, 2 mM Glutamax, N2 (Thermo Fisher, 17502048), B-27 (Thermo Fisher, 17504044)) supplemented with N-acetyl-L-cysteine (Sigma, A7250), 50 ng/ml murine EGF [ThermoFisher, PMG8041], 20% R-spondin-1 conditioned medium, (kind gift from Dr. Calvin Kuo), and 10% Noggin conditioned medium (kind gift from Dr. Hans Clevers). The organoids were maintained and passaged every 5–6 days regularly in incubator with 5% CO2 at 37°C.

Colon crypts isolation and colon organoid cultures

For isolation of colonic crypts, colon from WT and cKO mice was dissected and flushed with PBS. Next, distal colon was further taken for the isolation of colonic crypts. Colon was opened longitudinally and cut into small pieces (2–4 mm) and placed in 50 ml falcon having approximately 30 ml ice-cold PBS. These small fragments were washed with 30 ml of ice-cold PBS by pipetting up and down using 10 ml pipette coated with sterile FBS. After 5–6 washes, fragments were incubated with crypts isolation buffer (10 mM EDTA in PBS) for 45 minutes in cold room with slight agitation on rocker. After incubation, the crypt isolation buffer was discarded and 20 ml ice cold PBS was added. Next, to detach the crypts, vigorous pipetting with 10 ml pipette was performed and supernatant containing crypts was collected into fresh 50 ml tube coated with sterile FBS. This step was performed 5 to 6 times to collect as much as colonic crypts. Next, these crypts were spun down at 300 x g for 5 mins at 4° C. The crypts were resuspended in ice cold basal culture media. 10 μl of suspension was taken in small petri dish and counted for crypts under light microscope. After counting, approximate 200 colonic crypts were seeded in 40 μl of Matrigel per well and 50% WNR-conditioned media (WNR cell line L-WRN (ATCC CRL3276) in 24 well plate at 37°C in a 5% CO2 environment. Importantly, 50% WNR media was supplemented with 10 μM ROCK inhibitor (Y-27632) for first 2 days that improve the survival of crypts derived colon organoids. Normal 50% WNR media was added to all the wells after 2 days of incubation. After 7 days of incubation, colon organoids were formed from colonic crypts and matrigel was disrupted using 1 ml pipette and then split into more wells. Next, every 4 to 5 days, colon organoids were passaged and seeded for MUC2 immunofluoroscence imaging in IBIDI slides and RNA isolation in 24 well plate.

Bright field imaging and quantification of intestinal organoids

Bright field images of intestinal organoids were captured using a EVOS2 microscope with CO2, temperature, and a humidity-controlled incubation chamber (Thermo-Fisher Scientific). Z-stacks covering the entire Matrigel droplet with a 2X objective was captured for quantification. 2D morphological properties of organoid objects as well as their classification were gathered using a custom analysis program written in python based on opencv2. Further details of the program can be found in this pre-print [8]. To find the outline of organoids, the brightness of images was autoscaled to max brightness, and a canny edge detection algorithm was used on each individual z-plane. Pixel groups below a certain size were removed and a minimal projection of the edges was generated. This image was used to define the contour of objects. Opencv2s watershed algorithm was used to split somewhat overlapping objects from each other with the center of the object defined as the pixel furthest from the edge of the object. Each defined object contour was used to extract a 120x120 pixel picture of the object on a white background from a minimal projection of the original z-stack. These images were used to classify the organoid as either "Junk", "Budding" or "Spheroid" with a convolutional neural network implemented using Tensorflow and Keras [46].The network was trained on about 25 000 manually classified 120x120 images prepared as just described. Images were reviewed to see that segmentation and classification was adequate. [8]. No manual correction was done for the image quantification, but quantification was viewed for every image to see that segmentation and classification was adequate.

Organoid cultures and IF staining

For immunofluorescence assays, organoids were seeded in pre-warmed 8 well chamber IBIDI slides. After incubation, organoids were fixed in 4% paraformaldehyde with 2% sucrose for 30 minutes. Wells with fixed organoids were washed twice with sterile PBS for 5 mins each. Next, organoids were permeabilized with 0.2% Triton X 100 prepared in PBS and incubated for 30 min at room temperature. To block free aldehydes groups and prevent high background signal, organoids were incubated with 100 mM glycine for 1 h at room temperature. The organoids were then incubated in the blocking buffer (1% BSA, 2% NGS diluted in 0.2% Triton X 100 in PBS) in a humidified chamber for 1 h at room temperature. Organoids were incubated in the diluted primary antibody in the same blocking buffer for overnight at 4°C. Next day, the primary antibody anti ki67 (1:200 abcam ab15580), MUC2 (1:200 Santa Cruz Biotechnology sc-15334), β- catenin (1:200 Santa Cruz Biotechnology sc-7963), Filamin A (1:200 Invitrogen PA5-82043), RELMβ (1:200, Peprotech 500-p215) solution was decanted, and wells were washed three times for 10 minutes each with PBS with slight agitation. Organoids were incubated with secondary antibody (1:500, Goat anti-Rabbit IgG Alexa Fluor 488 Invitrogen A-11034 and Goat anti-Mouse IgG Alexa Fluor 647 Invitrogen A-21236), Ulex europaeus agglutinin-1 (UEA1, 1:500 Vector Laboratories RL-1062) and DAPI (1:1000) counterstained for overnight at 4°C in the dark. Next, secondary antibody solution was decanted, and wells were washed three times with PBS for 10 minutes in agitation. After staining, wells were mounted in 250 μL of Fluoromount G and were visualized with a confocal microscope.

Quantification of fluorescence intensity and specific cell markers

For quantification of fluorescence intensity in organoids, confocal images were opened using FIJI software. Images were stacked using the Z project and sum slices were made. After that, all the color channels were split and threshold for each channel was calculated. Next, organoids were selected manually and fluorescence intensity for each color channel was calculated per each organoid area. For normalization, the fluorescence intensity of target protein such as Ki67, Filamin A and MUC2 was divided by fluorescence intensity of DAPI and plotted in the graphs. Graphs show quantification of 2 to 3 biological replicates, with 100–150 small intestine organoids and colon organoids (≈50) per condition and each dot represents one organoid. For quantification of RELMβ+, MUC2+, Ki67+and UEA1+cells in organoids and crypts, these positive cells were manually counted in ZEN 2.3 blue edition software.

FITC dextran assay to assess epithelial barrier integrity

FITC dextran assay was performed in naive, WT and cKO mice infected with C. rodentium for 6 days. Briefly, on the day 6 post infection, 4 kDa fluorescein isothiocyanate (FITC)-dextran (Sigma-Aldrich, FD4-1G) was dissolved in PBS at a concentration of 80 mg per ml. After that, mice were orally gavage with 150 μl of FITC-dextran and food was withdrawn for next 4 hours. After 4 hours, mice were anesthetized using isoflurane and blood was collected through cardiac puncture. The blood was added immediately to the tubes containing heparin with final concentration of 1 IU. The tubes with blood were mixed properly and kept on ice. To collect serum, blood samples were centrifuged at 1,000 x g for 12 minutes at 4°C. Serum was collected and diluted to 1:1 in PBS. After that, 100μl of diluted serum was added to the 96 well black-walled, clear-bottom plates in replicates. In addition, a standard curve was prepared by dilution 80 mg per ml FITC-dextran to 25 μg, 12.5 and until 8 half dilutions. The fluorescence of FITC- dextran was acquired at fluorometer (POLARstar Omega) at an excitation wavelength of 485 nm and 520 nm emission wavelength. After acquisition, a standard curve was plotted to determine the concentration of FITC-dextran in serum derived from different mice groups.

Western blot analysis

Total protein was extracted from the organoids. Briefly, organoids were harvested and resuspended in RIPA Lysis and Extraction Buffer supplemented with PhosSTOP Phosphatase Inhibitor Cocktail for 10mins in ice. Proteins (50μg) were separated by NuPAGE Bis-Tris protein precast polyacrylamide gels and transferred to nitrocellulose membranes using iBlot 2 Gel Transfer device. The membranes were incubated with 5% blocking buffer (5% BSA in TBST) for 1h at room temperature. The membranes were further incubated with the primary antibodies against p-STAT3 (1:2000, Cell Signaling Technology, 9145), STAT3 (1:1000, Cell Signaling Technology, 9139) and GAPDH (1:5000, abcam ab125247) for overnight at 4°C. Next day, after three washes with TBST for 5 mins, membranes were incubated with secondary antibody conjugated with horseradish peroxidase for 1 h at room temperature. Again, membranes were washed three times with TBST for 5 minutes and were visualized with Super Signal West Femto Maximum Sensitivity Substrate and images were acquired using Licor Odyssey detection system.

Mesenteric lymph nodes isolation and CD3/CD28 restimulation

The mesenteric lymph nodes were isolated from naïve or infected mice and kept in sterile PBS. Harvested lymph nodes from individual mouse were passed through 70 μm cell strainer for single cell suspension. The cell viability was assessed using Trypan blue and counted using Countess automated cell counter (Invitrogen). The cells were resuspended in DMEM and adjusted to 2×105 cells per well. A solution of anti-mouse CD3e (100314, Biolegend) was prepared at 5 μg/mL in sterile PBS and 50 μl of antibody solution was added into 96 well plate followed by incubation at 37°C for 2 hours. The antibody solution was removed with a multichannel pipettor and single cell suspension of lymph node cells (2×105 cells per well) was added to respective wells in coated 96 well plates. Next, soluble anti-mouse CD28 (102112, Biolegend) was added to cells at 2 μg/mL. Cells were incubated for 4 days to induce proliferation of cells. After incubation, cells were centrifuged and supernatant was collected for cytokine analysis by ELISA.

Flow cytometry

Colon from WT and cKO mice were dissected and flushed by PBS. Colon was open longitudinally and cut into small piece of fragments. These fragments were further washed with cold PBS until the supernatant was clear. Next, the colon fragments were incubated with crypts isolation buffer (20mM EDTA in PBS) for 45 minutes at cold room with slight agitation. After incubation, EDTA buffer was removed and fragments were vigorously resuspended in 20ml of ice chilled PBS by shaking and 10mL pipette. The supernatant with crypts was collected in 50ml falcon tube coated with FBS. Next, supernatant with crypts was centrifuged at 300 g for 5 minutes at 4°C to pellet down the crypts. Crypts were further resuspended in TryplE express for 30 minutes at 37°C and were dissociated with pipette every 5 minutes. Digested crypts cells were incubated with anti-mouse TruStain Fc (1:400, BioLegend 101320) for 5 minutes in ice. Cells were further stained with Alexa Fluor 488 anti-mouse SCA1 antibody (1:200, BioLegend 108116) and other epithelial cells markers (anti-mouse CD326 Brilliant Violet 605, 1:200 Biolegend 118227, and PerCP/Cy5.5 anti-mouse CD24, 1:200 Biolegend 101824) for 20 minutes at 4°C, twice washed with PBS and incubated with DAPI for 3 minutes in the last step. Before acquisition, cells suspension was passed through a 70 μm filter mesh. All the samples were acquired using a BD LSR II flow cytometer (BD Biosciences) and analyzed using FlowJo software.

Statistical analysis

The statistical analysis was performed using the Graph Pad Prism. Unpaired two-tailed Student’s t test and One-way analysis of variance with Tukey’s Multiple Comparison Test were used to determine the Statistically significant differences between the different experimental groups and P value of <0.05 was considered significant. All the Statistical tests used are described in the figure legends. All numerical data used to make the figures is reported in S1 Data.

Supporting information

S1 Fig. Incomplete deletion of Lsd1 in Villin-Cre Lsd1f/f (cKO) mice.

(A) Confocal microscope images of whole colon swiss roles stained for LSD1 (green) expression comparing naive WT and cKO mice. DAPI (blue) was used as a nuclear counterstain. (B) LSD1 expression in WT and cKO colon WT(n = 5) and cKO (n = 3).

(TIF)

S2 Fig. Gating strategy for SCA-1 in colonic crypts.

(A) Gating strategy used for flow cytometry plots to determine DAPI- (live) EPCAM+ (epithelial) cells.

(TIF)

S3 Fig. Escaper crypts in cKO mice have WT features.

(A) Immunofluorescence staining to check co-localization of LSD1 (green) and RELMβ (green) in colon sections of cKO mice infected with C.rodentium for 6 days. DAPI (blue) was used as a counterstain. Original magnification: 10 X and scale bar- 50μm. (B) Immunofluorescence staining of FLNA (green) in colon sections from naïve cKO mice. White arrow indicates that there is no FLNA expression in WT escaper crypt. Original magnification: 20 X and scale bar- 50μm.

(TIF)

S4 Fig. GSK-LSD1 treatment downregulates Goblet cells in organoids.

(A) RT- qPCR for Muc2 expression in organoids left untreated or treated with GSK-LSD1 for 4 days. Expression was normalized to housekeeping gene Hprt. (B) Immunofluorescent images of MUC2 (green), UEA1 (red) and DAPI (Blue) in WT organoids that were cultured in normal culture medium (ENR = EGF, NOGGIN, R-SPONDIN) or in ENR medium supplemented with GSK-LSD1 for 4 days. Scale bar is 50 μm.

(TIF)

S5 Fig. cKO colon organoids have negligible LSD1 and Muc2 expression.

(A) Immunofluorescent staining of LSD1 (green), UEA1 (red) and DAPI (blue) in WT and cKO colon organoids was performed. Scale bar is 50 μm. (B) RT- qPCR for Muc2 expression in WT and cKO colon organoids cultured in ENR for 4 days. Expression was normalized to housekeeping gene Hprt.

(TIF)

S1 Table. Supplementary table 1 for primers information.

(DOCX)

S1 Data. Numerical values: Data file that includes all numerical values used to make graphs.

(XLSX)

Acknowledgments

We thank Drs. Stuart Orkin and Sylvie Robine for kindly sharing mouse strains. We thank the imaging (CMIC), genomics (GCF), and animal care (CoMed) core facilities that assisted in this work (NTNU). BAV is the CH.I.L.D. Foundation Chair in Pediatric Gastroenterology.

Data Availability

All relevant data are within the manuscript and its Supporting Information files, except for the ATAC sequencing, which is deposited: E-MTAB-8718.

Funding Statement

Funding of this work was provided by the Norwegian Research Council (Centre of Excellence grant 223255/F50, and ‘Young Research Talent’ 274760 to MJO) and the Norwegian Cancer Society (182767 to MJO). MMA is the recipient of a Marie Skłodowska-Curie IF (DLV-794391). This work was also supported by the South‐Eastern Norway Regional Health Authority, Early Career Grant 2016058, and the Research Council of Norway “Young Research Talent” grant to JAD. KB is a Banting Fellow. MF is supported by the Norwegian Research Council (grant no. 275286). CZ is supported by the Australian National Health and Medical Research Council (APP1104433 and APP1104466). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Kirk MD, Pires SM, Black RE, Caipo M, Crump JA, Devleesschauwer B, et al. World Health Organization Estimates of the Global and Regional Disease Burden of 22 Foodborne Bacterial, Protozoal, and Viral Diseases, 2010: A Data Synthesis. Seidlein von L, editor. PLoS Med. 2015;12: e1001921. 10.1371/journal.pmed.1001921 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Carlet J. The gut is the epicentre of antibiotic resistance. Antimicrob Resist Infect Control. 2012;1: 39–7. 10.1186/2047-2994-1-39 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Allaire JM, Crowley SM, Law HT, Chang S-Y, Ko H-J, Vallance BA. The Intestinal Epithelium: Central Coordinator of Mucosal Immunity. Trends in Immunology. Elsevier Ltd; 2018;39: 1–20. 10.1016/j.it.2017.11.005 [DOI] [PubMed] [Google Scholar]
  • 4.Bevins CL, Salzman NH. Paneth cells, antimicrobial peptides and maintenance of intestinal homeostasis. Nat Rev Microbiol. 2011;9: 356–368. 10.1038/nrmicro2546 [DOI] [PubMed] [Google Scholar]
  • 5.Kim YS, Ho SB. Intestinal goblet cells and mucins in health and disease: recent insights and progress. Curr Gastroenterol Rep. Current Science Inc; 2010;12: 319–330. 10.1007/s11894-010-0131-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Ting H-A, Moltke JV. The immune function of tuft cells at gut mucosal surfaces and beyond. J Immunol. 2019;202: 1321–1329. 10.4049/jimmunol.1801069 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Biton M, Haber AL, Rogel N, Burgin G, Beyaz S, Schnell A, et al. T Helper Cell Cytokines Modulate Intestinal Stem Cell Renewal and Differentiation. Cell. 2018;175: 1307–1320.e22. 10.1016/j.cell.2018.10.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Lindholm HT, Parmar N, Drurey C, Ostrop J, Díez-Sánchez A, Maizels RM, et al. Developmental pathways regulate cytokine-driven effector and feedback responses in the intestinal epithelium. bioRxiv. Cold Spring Harbor Laboratory; 2020;: 2020.06.19.160747. 10.1101/2020.06.19.160747 [DOI] [Google Scholar]
  • 9.Yui S, Azzolin L, Maimets M, Maimets M, Pedersen MT, Pedersen MT, et al. YAP/TAZ-Dependent Reprogramming of Colonic Epithelium Links ECM Remodeling to Tissue Regeneration. Cell Stem Cell. 2018;22: 35–49.e7. 10.1016/j.stem.2017.11.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Wang Y, Chiang I-L, Ohara TE, Fujii S, Cheng J, Muegge BD, et al. Long-Term Culture Captures Injury-Repair Cycles of Colonic Stem Cells. Cell. Elsevier Inc; 2019;179: 1144–1159.e15. 10.1016/j.cell.2019.10.015 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Cai J, Zhang N, Zheng Y, de Wilde RF, Maitra A, Pan D. The Hippo signaling pathway restricts the oncogenic potential of an intestinal regeneration program. Genes Dev. Cold Spring Harbor Lab; 2010;24: 2383–2388. 10.1101/gad.1978810 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Kouzarides T. Chromatin modifications and their function. Cell. 2007 ed. 2007;128: 693–705. 10.1016/j.cell.2007.02.005 [DOI] [PubMed] [Google Scholar]
  • 13.Chiacchiera F, Rossi A, Jammula S, Zanotti M, Pasini D. PRC2 preserves intestinal progenitors and restricts secretory lineage commitment. Embo J. EMBO Press; 2016;35: 2301–2314. 10.15252/embj.201694550 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Jadhav U, Nalapareddy K, Saxena M, O’Neill NK, Pinello L, Yuan G-C, et al. Acquired Tissue-Specific Promoter Bivalency Is a Basis for PRC2 Necessity in Adult Cells. Cell. Elsevier Inc; 2016;165: 1389–1400. 10.1016/j.cell.2016.04.031 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Koppens MAJ, Bounova G, Gargiulo G, Tanger E, Janssen H, Cornelissen-Steijger P, et al. Deletion of Polycomb Repressive Complex 2 From Mouse Intestine Causes Loss of Stem Cells. Gastroenterology. 2016;151: 684–697.e12. 10.1053/j.gastro.2016.06.020 [DOI] [PubMed] [Google Scholar]
  • 16.Zwiggelaar RT, Lindholm HT, Fosslie M, Terndrup Pedersen M, Ohta Y, Díez-Sánchez A, et al. LSD1 represses a neonatal/reparative gene program in adult intestinal epithelium. Sci Adv. 2020;6: eabc0367. 10.1126/sciadv.abc0367 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell. 2004;119: 941–953. 10.1016/j.cell.2004.12.012 [DOI] [PubMed] [Google Scholar]
  • 18.Nusse YM, Nusse YM, Savage AK, Savage AK, Marangoni P, Marangoni P, et al. Parasitic helminths induce fetal-like reversion in the intestinal stem cell niche. Nature. 2018;559: 109–113. 10.1038/s41586-018-0257-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Lindemans CA, Calafiore M, Mertelsmann AM, O’Connor MH, Dudakov JA, Jenq RR, et al. Interleukin-22 promotes intestinal-stem-cell-mediated epithelial regeneration. Nature. 2015;528: 560–564. 10.1038/nature16460 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Zheng Y, Valdez PA, Danilenko DM, Hu Y, Sa SM, Gong Q, et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nature Medicine. Nature Publishing Group; 2008;14: 282–289. 10.1038/nm1720 [DOI] [PubMed] [Google Scholar]
  • 21.Collins JW, Keeney KM, Crepin VF, Rathinam VAK, Fitzgerald KA, Finlay BB, et al. Citrobacter rodentium: infection, inflammation and the microbiota. Nat Rev Microbiol. 2014;12: 612–623. 10.1038/nrmicro3315 [DOI] [PubMed] [Google Scholar]
  • 22.Bergstrom KSB, Kissoon-Singh V, Gibson DL, Ma C, Montero M, Sham HP, et al. Muc2 Protects against Lethal Infectious Colitis by Disassociating Pathogenic and Commensal Bacteria from the Colonic Mucosa. Roy CR, editor. 2010;6: e1000902–25. 10.1371/journal.ppat.1000902 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Papapietro O, Teatero S, Thanabalasuriar A, Yuki KE, Diez E, Zhu L, et al. R-spondin 2 signalling mediates susceptibility to fatal infectious diarrhoea. Nat Commun. 2013;4: 1898. 10.1038/ncomms2816 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Cliffe LJ, Humphreys NE, Lane TE, Potten CS, Booth C, Grencis RK. Accelerated intestinal epithelial cell turnover: a new mechanism of parasite expulsion. Science. American Association for the Advancement of Science; 2005;308: 1463–1465. 10.1126/science.1108661 [DOI] [PubMed] [Google Scholar]
  • 25.Oudhoff MJ, Antignano F, Chenery AL, Burrows K, Redpath SA, Braam MJ, et al. Intestinal Epithelial Cell-Intrinsic Deletion of Setd7 Identifies Role for Developmental Pathways in Immunity to Helminth Infection. PLoS Pathog. 2016;12: e1005876. 10.1371/journal.ppat.1005876 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Hasnain SZ, Wang H, Ghia JE, Haq N, Deng Y, Velcich A, et al. Mucin gene deficiency in mice impairs host resistance to an enteric parasitic infection. Gastroenterology. 2010;138: 1763–1771. 10.1053/j.gastro.2010.01.045 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Turner J-E, Stockinger B, Helmby H. IL-22 Mediates Goblet Cell Hyperplasia and Worm Expulsion in Intestinal Helminth Infection. Wynn TA, editor. Public Library of Science; 2013;9: e1003698–7. 10.1371/journal.ppat.1003698 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Yin X, Farin HF, van Es JH, Clevers H, Langer R, Karp JM. Niche-independent high-purity cultures of Lgr5(+) intestinal stem cells and their progeny. Nat Methods. 2013;11: 106–112. 10.1038/nmeth.2737 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Haber AL, Biton M, Rogel N, Herbst RH, Shekhar K, Smillie C, et al. A single-cell survey of the small intestinal epithelium. Nature. 2017;551: 333–339. 10.1038/nature24489 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Mohammad HP, Smitheman KN, Kamat CD, Soong D, Federowicz KE, Van Aller GS, et al. A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC. Cancer Cell. Elsevier Inc; 2015;28: 57–69. 10.1016/j.ccell.2015.06.002 [DOI] [PubMed] [Google Scholar]
  • 31.Wiener Z, Högström J, Hyvönen V, Band AM, Kallio P, Holopainen T, et al. Prox1 promotes expansion of the colorectal cancer stem cell population to fuel tumor growth and ischemia resistance. CellReports. 2014;8: 1943–1956. 10.1016/j.celrep.2014.08.034 [DOI] [PubMed] [Google Scholar]
  • 32.McWhorter FY, Wang T, Nguyen P, Chung T, Liu WF. Modulation of macrophage phenotype by cell shape. PNAS. 2013;110: 17253–17258. 10.1073/pnas.1308887110 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Petersen N, Frimurer TM, Pedersen MT, Egerod KL, Albrechtsen NJW, Holst JJ, et al. Inhibiting RHOA Signaling in Mice Increases Glucose Tolerance and Numbers of Enteroendocrine and Other Secretory Cells in the Intestine. Gastroenterology. Elsevier, Inc; 2018;155: 1164–1176.e2. 10.1053/j.gastro.2018.06.039 [DOI] [PubMed] [Google Scholar]
  • 34.Oh C, Jeong J, Oh SK, Baek SH, Kim KI. Inhibition of LSD1 phosphorylation alleviates colitis symptoms induced by dextran sulfate sodium. BMB Rep. Korean Society for Biochemistry and Molecular Biology; 2020;53: 385–390. 10.5483/BMBRep.2020.53.7.298 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Razinia Z, Mäkelä T, Ylänne J, Calderwood DA. Filamins in mechanosensing and signaling. Annu Rev Biophys. 2012;41: 227–246. 10.1146/annurev-biophys-050511-102252 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Maiques-Diaz A, Spencer GJ, Lynch JT, Ciceri F, Williams EL, Amaral FMR, et al. Enhancer Activation by Pharmacologic Displacement of LSD1 from GFI1 Induces Differentiation in Acute Myeloid Leukemia. CellReports. 2018;22: 3641–3659. 10.1016/j.celrep.2018.03.012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Shroyer NF, Wallis D, Venken KJT, Bellen HJ, Zoghbi HY. Gfi1 functions downstream of Math1 to control intestinal secretory cell subtype allocation and differentiation. Genes Dev. 2005 ed. 2005;19: 2412–2417. 10.1101/gad.1353905 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Mendenhall EM, Williamson KE, Reyon D, Zou JY, Ram O, Joung JK, et al. Locus-specific editing of histone modifications at endogenous enhancers. Nature Biotechnology. 2013;31: 1133–1136. 10.1038/nbt.2701 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Marjou El F, Janssen K-P, Chang BH-J, Li M, Hindie V, Chan L, et al. Tissue-specific and inducible Cre-mediated recombination in the gut epithelium. Genesis. 2004 ed. 2004;39: 186–193. 10.1002/gene.20042 [DOI] [PubMed] [Google Scholar]
  • 40.Kerenyi MA, Shao Z, Hsu Y-J, Guo G, Luc S, O’Brien K, et al. Histone demethylase Lsd1 represses hematopoietic stem and progenitor cell signatures during blood cell maturation. Elife. 2013;2: e00633. 10.7554/eLife.00633 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Yu G, Wang L-G, Han Y, He Q-Y. ClusterProfiler: An R package for comparing biological themes among gene clusters. OMICS. 2012;16: 284–287. 10.1089/omi.2011.0118 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz G, et al. Integrative genomics viewer. Nature Biotechnology. Nature Publishing Group; 2011;29: 24–26. 10.1038/nbt.1754 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Buenrostro JD, Giresi PG, Zaba LC, Chang HY, Greenleaf WJ. Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. Nat Methods. Nature Publishing Group; 2013;10: 1213–1218. 10.1038/nmeth.2688 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Corces MR, Trevino AE, Hamilton EG, Greenside PG, Sinnott-Armstrong NA, Vesuna S, et al. An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues. Nat Methods. Nature Publishing Group; 2017;14: 959–962. 10.1038/nmeth.4396 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Sato T, Clevers H. Primary mouse small intestinal epithelial cell cultures. Methods Mol Biol. Totowa, NJ: Humana Press; 2013;945: 319–328. 10.1007/978-1-62703-125-7_19 [DOI] [PubMed] [Google Scholar]
  • 46.Abadi M, Agarwal A, Barham P, Brevdo E, Chen Z, Citro C, et al. TensorFlow: Large-Scale Machine Learning on Heterogeneous Distributed Systems. 2016. [Google Scholar]

Decision Letter 0

Nina R Salama, Eric Oswald

1 Feb 2021

Dear Mr. Oudhoff,

Thank you very much for submitting your manuscript "Intestinal-epithelial LSD1 controls goblet cell differentiation and effector responses required for gut immunity to bacterial and helminth infection" for consideration at PLOS Pathogens. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. In light of the reviews (below this email), we would like to invite the resubmission of a significantly-revised version that takes into account the reviewers' comments.

The revised version of your manuscript has been reviewed by 3 of the 4 reviewers who initially had the first version. While all of them recognized the clear improvement of the manuscript, one of the reviewers (an expert in intestinal epithelial homeostasis) found that there are still some experiments that are necessary to justify your conclusions. I agree with him that it is necessary for you to meet his expectations (and in particular the use of colon organoids) while being more critical of the results and the conclusions that follow.

We cannot make any decision about publication until we have seen the revised manuscript and your response to the reviewers' comments. Your revised manuscript is also likely to be sent to reviewers for further evaluation.

When you are ready to resubmit, please upload the following:

[1] A letter containing a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript. Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

[2] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Please prepare and submit your revised manuscript within 60 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email. Please note that revised manuscripts received after the 60-day due date may require evaluation and peer review similar to newly submitted manuscripts.

Thank you again for your submission. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments.

Sincerely,

Eric Oswald, Ph.D., D.V.M.

Associate Editor

PLOS Pathogens

Nina Salama

Section Editor

PLOS Pathogens

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0001-5065-158X

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

***********************

The revised version of your manuscript has been reviewed by 3 of the 4 reviewers who initially had the first version. While all of them recognized the clear improvement of the manuscript, one of the reviewers (an expert in intestinal epithelial homeostasis) found that there are still some experiments that are necessary to justify your conclusions. I agree with him that it is necessary for you to meet his expectations (and in particular the use of colon organoids) while being more critical of the results and the conclusions that follow.

Reviewer's Responses to Questions

Part I - Summary

Please use this section to discuss strengths/weaknesses of study, novelty/significance, general execution and scholarship.

Reviewer #1: The authors have now refocused their story on the role of LSD1 in goblet cell differentiation and activity using two different models of infection.

In its present form the manuscript is way more convincing and vehicle a clear message.

Reviewer #2: This revised version of the manuscript has been greatly improved. The authors have done a nice job by addressing most of the comments and adding supporting additional data.

Reviewer #3: This study explores the role of the histone demethylase LSD1 in intestinal pathophysiology, which is a topic of broad interest to the medical, as well as cell biology community. In summary, the authors characterised the effects of LSD1 invalidation on colonic epithelial homeostasis and repair upon infection, using an in vivo approach (colon tissue). Their work points to an important role of LSD1 in epithelial tissue homeostasis via the regulation of a goblet cell-specific response to infection.

The authors claim that LSD1 also controls goblet cell differentiation; however, this cannot be assessed solely on the basis of markers and approaches used in this study.

I also have reservations regarding (i) the use of small intestinal organoids to model a colon-specific response to infection, and (ii) the fact that the published RNAseq data the authors rely on is from small intestinal crypts; this confounds their GSEA and GO analyses in the current paper. The strongest conclusions in this paper are obtained from experiments on colon tissue, which is indeed the relevant tissue for this study, considering the pathophysiological scope of this work using infection models that specifically target the large intestine. I find that more data would be needed to reinforce certain conclusions, as well as a more thorough discussion of the observed effects, especially with regard to the consequences of upregulation of filamin A and/or other cytoskeletal regulators/organisation, and how this could reflect on goblet cell-specific response, observed in their experiments.

**********

Part II – Major Issues: Key Experiments Required for Acceptance

Please use this section to detail the key new experiments or modifications of existing experiments that should be absolutely required to validate study conclusions.

Generally, there should be no more than 3 such required experiments or major modifications for a "Major Revision" recommendation. If more than 3 experiments are necessary to validate the study conclusions, then you are encouraged to recommend "Reject".

Reviewer #1: N/A

Reviewer #2: None

Reviewer #3: 1. Assessing goblet cell differentiation based only on immunostaining for Muc2 and RELMB, PAS staining or lectin-binding capacity (UEA1), is problematic. As the authors themselves stated in their response to reviewer 3, (2/Figure 6) “MUC2 can be secreted, and thus these cells cannot be counted; UEA1, in our hands, is not always a reliable marker for goblet cells, especially in organoids (i.e. we have MUC2+ cells that are UEA1-)”. Also, the relationship between Muc2 and RELMB does not seem to be trivial (RELMB was dramatically upregulated in Muc2-/- mice; see Morambudi et al. 2016; PMID: 26813339). Moreover, judging from the image of the colon crypts (63X; E-cad, DAPI) that was provided in response to my concerns in the previous revision, many cells with goblet-like morphology are still present in the cKO. Thus, considering the complexity of assessing cell identity/differentiation, my suggestion is that the focus of the study should remain on goblet cell effector responses in LSD1-KO and infection models, which are well established in this study, and not in a role of LSD1 in goblet differentiation, for which the evidence is not enough.

2. Authors should address the role of LSD1-KO in colon organoids, in order to be consistent with the organ and epithelial tissue they are addressing in their in vivo experiments. Authors’ reasoning to use small intestinal (SI) organoids as a model in this study was based on less efficient recombination of LSD1-KO in the colon and, more importantly, the fact that colon organoids culture requires Wnt, which results in incomplete differentiation. According to Sato et al. 2011a (PMID: 21889923), Wnt can be removed (“differentiation medium”) which then allows for complete differentiation. Please note that Sato et al. assessed epithelial cell differentiation in cultured colon organoids by measuring mRNA expression of various markers (Muc2, ChgA, Alpi..) and thus did not solely rely on immunostaining or lectin binding.

3. Authors claim that “FILAMIN A, a key protein in mechanosensing and mechanotransduction (references are missing), is a direct target of LSD1 demethylase activity” yet they don’t try to functionally validate this proposed role of filamin A in the colon, so this seems to be an exaggeration. I suggest that the authors refrain from such statements unless they are able to tackle and explain the role of filamin A in this context, assuming there were more candidates coming from the screen. As it stands, filamin A and its increased expression in this study represents an example confirming their RNAseq screen and the follow-up analysis.

4. Authors used ROCK1 inhibitor to perturb “cytoskeletal organization”, which in itself sounds very vague. They should explain the rationale for this approach and discuss the results of this treatment in the context of what is known or proposed for this kinase inhibitor, including the maintenance and differentiation of stem cells, in addition to the well-studied effect on actomyosin contractility, which was not mentioned or discussed either.

**********

Part III – Minor Issues: Editorial and Data Presentation Modifications

Please use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity.

Reviewer #1: (No Response)

Reviewer #2: None

Reviewer #3: 1. Line 452: Methods: “Bright field imaging and quantification of intestinal organoids” - instead of referring to their preprint, authors should explain in this paragraph how their images were quantified.

2. Line 100-101: LSD1 expression in colon cKO is not quantitated.

3. Fig. 1G, H, S2B: Western blot should be repeated and quantified (gel band densitometry). Authors need to clearly assess whether STAT phosphorylation response is the same or weaker upon IL-22 induction in cKO. The confocal images of organoids in S2B were not quantified either.

4. Line 131-132: increased mortality and weight loss are relatively mild, especially at day 6 pi. Why not looking at later stages?

5. Line 137-139: the effects of Citrobacter infection on the gut barrier permeability should be more clearly explained in the text. The barrier permeability was increased upon Citro infection, but there was no significant difference between the ctrl and the KO at day 6 pi.

6. Figs. 2-3C, F, G: Authors should provide data also for naïve crypts (ideally for both wt and cKO).

7. Fig. 3D, F: Authors should be explicit on whether they analysed crypts from the same region of the colon, as crypt length varies significantly between different regions of colon (PMID: 24205248)

8. Fig. S3A: These images are seemingly not from the same focal plane (or perhaps not the same region), so it is impossible to determine “colocalization”; also, “escaper” crypts should be somehow highlighted.

9. Line 182-183: can authors explain why the crypt length is different for WT and cKO between Citro and T. muris conditions (Fig. 3C vs 4G)?

10. Line 197: “we found that goblet cell differentiation and maturation is much more

impaired in the colons of naïve cKO mice, as shown by reduced numbers (differentiation)…”. Authors should be more careful – they did not show numbers of goblet cells (they show number of Muc2+ and UEA1+ cells per crypt, as stated in Fig. 5B and C).

11. Line 224: Authors used data from RNAseq performed on SI crypts cKO/WT and GSK-LSD1/untreated organoids and gene enrichment analysis, instead of performing this analysis on colon tissue/organoids. It should be explained why they did not analyse colon tissue/organoids.

12. Line 259: hyphen missing (LSD1 controlled)

13. Line 263: "induce MUC2 expression" would be more correct

14. Line 295: remove colitis, as those experiments were removed

15. Line 316: GFI1-KO mice were shown to have decreased goblet cell numbers/maturation, and not a complete lack of – this should be corrected.

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: tiffany bouchery

Reviewer #2: Yes: Chamaillard

Reviewer #3: No

Figure Files:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

Data Requirements:

Please note that, as a condition of publication, PLOS' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here on PLOS Biology: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5.

Reproducibility:

To enhance the reproducibility of your results, PLOS recommends that you deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see http://journals.plos.org/plospathogens/s/submission-guidelines#loc-materials-and-methods

Decision Letter 1

Nina R Salama, Eric Oswald

14 Mar 2021

Dear Mr. Oudhoff,

We are pleased to inform you that your manuscript 'Intestinal-epithelial LSD1 controls goblet cell maturation and effector responses required for gut immunity to bacterial and helminth infection' has been provisionally accepted for publication in PLOS Pathogens.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Pathogens.

Best regards,

Eric Oswald, Ph.D., D.V.M.

Associate Editor

PLOS Pathogens

Nina Salama

Section Editor

PLOS Pathogens

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0001-5065-158X

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

***********************************************************

Reviewer Comments (if any, and for reference):

Acceptance letter

Nina R Salama, Eric Oswald

25 Mar 2021

Dear Mr. Oudhoff,

We are delighted to inform you that your manuscript, "Intestinal-epithelial LSD1 controls goblet cell maturation and effector responses required for gut immunity to bacterial and helminth infection," has been formally accepted for publication in PLOS Pathogens.

We have now passed your article onto the PLOS Production Department who will complete the rest of the pre-publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Pearls, Reviews, Opinions, etc...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript, if you opted to have an early version of your article, will be published online. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Pathogens.

Best regards,

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0001-5065-158X

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Incomplete deletion of Lsd1 in Villin-Cre Lsd1f/f (cKO) mice.

    (A) Confocal microscope images of whole colon swiss roles stained for LSD1 (green) expression comparing naive WT and cKO mice. DAPI (blue) was used as a nuclear counterstain. (B) LSD1 expression in WT and cKO colon WT(n = 5) and cKO (n = 3).

    (TIF)

    S2 Fig. Gating strategy for SCA-1 in colonic crypts.

    (A) Gating strategy used for flow cytometry plots to determine DAPI- (live) EPCAM+ (epithelial) cells.

    (TIF)

    S3 Fig. Escaper crypts in cKO mice have WT features.

    (A) Immunofluorescence staining to check co-localization of LSD1 (green) and RELMβ (green) in colon sections of cKO mice infected with C.rodentium for 6 days. DAPI (blue) was used as a counterstain. Original magnification: 10 X and scale bar- 50μm. (B) Immunofluorescence staining of FLNA (green) in colon sections from naïve cKO mice. White arrow indicates that there is no FLNA expression in WT escaper crypt. Original magnification: 20 X and scale bar- 50μm.

    (TIF)

    S4 Fig. GSK-LSD1 treatment downregulates Goblet cells in organoids.

    (A) RT- qPCR for Muc2 expression in organoids left untreated or treated with GSK-LSD1 for 4 days. Expression was normalized to housekeeping gene Hprt. (B) Immunofluorescent images of MUC2 (green), UEA1 (red) and DAPI (Blue) in WT organoids that were cultured in normal culture medium (ENR = EGF, NOGGIN, R-SPONDIN) or in ENR medium supplemented with GSK-LSD1 for 4 days. Scale bar is 50 μm.

    (TIF)

    S5 Fig. cKO colon organoids have negligible LSD1 and Muc2 expression.

    (A) Immunofluorescent staining of LSD1 (green), UEA1 (red) and DAPI (blue) in WT and cKO colon organoids was performed. Scale bar is 50 μm. (B) RT- qPCR for Muc2 expression in WT and cKO colon organoids cultured in ENR for 4 days. Expression was normalized to housekeeping gene Hprt.

    (TIF)

    S1 Table. Supplementary table 1 for primers information.

    (DOCX)

    S1 Data. Numerical values: Data file that includes all numerical values used to make graphs.

    (XLSX)

    Attachment

    Submitted filename: ParmarRebuttal.docx

    Attachment

    Submitted filename: Parmar Rebuttal second revision.docx

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting Information files, except for the ATAC sequencing, which is deposited: E-MTAB-8718.


    Articles from PLoS Pathogens are provided here courtesy of PLOS

    RESOURCES